Unknown

Dataset Information

0

Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.


ABSTRACT: PURPOSE:Clinical trials in early breast cancer have suggested that benefits of adjuvant bone-targeted treatments are restricted to women with established menopause. We developed models that mimic pre- and postmenopausal status to investigate effects of altered bone turnover on growth of disseminated breast tumor cells. Here, we report a differential antitumor effect of zoledronic acid (ZOL) in these two settings. EXPERIMENTAL DESIGN:Twleve-week-old female Balb/c-nude mice with disseminated MDA-MB-231 breast tumor cells in bone underwent sham operation or ovariectomy (OVX), mimicking the pre- and postmenopausal bone microenvironment, respectively. To determine the effects of bone-targeted therapy, sham/OVX animals received saline or 100 ?g/kg ZOL weekly. Tumor growth was assessed by in vivo imaging and effects on bone by real-time PCR, micro-CT, histomorphometry, and measurements of bone markers. Disseminated tumor cells were detected by two-photon microscopy. RESULTS:OVX increased bone resorption and induced growth of disseminated tumor cells in bone. Tumors were detected in 83% of animals following OVX (postmenopausal model) compared with 17% following sham operation (premenopausal model). OVX had no effect on tumors outside of bone. OVX-induced tumor growth was completely prevented by ZOL, despite the presence of disseminated tumor cells. ZOL did not affect tumor growth in bone in the sham-operated animals. ZOL increased bone volume in both groups. CONCLUSIONS:This is the first demonstration that tumor growth is driven by osteoclast-mediated mechanisms in models that mimic post- but not premenopausal bone, providing a biologic rationale for the differential antitumor effects of ZOL reported in these settings. Clin Cancer Res; 20(11); 2922-32. ©2014 AACR.

SUBMITTER: Ottewell PD 

PROVIDER: S-EPMC4040234 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.

Ottewell Penelope D PD   Wang Ning N   Brown Hannah K HK   Reeves Kimberly J KJ   Fowles C Anne CA   Croucher Peter I PI   Eaton Colby L CL   Holen Ingunn I  

Clinical cancer research : an official journal of the American Association for Cancer Research 20140331 11


<h4>Purpose</h4>Clinical trials in early breast cancer have suggested that benefits of adjuvant bone-targeted treatments are restricted to women with established menopause. We developed models that mimic pre- and postmenopausal status to investigate effects of altered bone turnover on growth of disseminated breast tumor cells. Here, we report a differential antitumor effect of zoledronic acid (ZOL) in these two settings.<h4>Experimental design</h4>Twleve-week-old female Balb/c-nude mice with dis  ...[more]

Similar Datasets

| S-EPMC7516134 | biostudies-literature
| S-EPMC5581539 | biostudies-literature
| S-EPMC9030653 | biostudies-literature
| S-EPMC8624848 | biostudies-literature
| S-EPMC8559775 | biostudies-literature
| S-EPMC4278054 | biostudies-literature
| S-EPMC9727731 | biostudies-literature
| S-EPMC4971333 | biostudies-literature
| S-EPMC7203488 | biostudies-literature
| S-EPMC5421845 | biostudies-literature